Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2007-05-08
2007-05-08
Sullivan, Daniel M. (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S091400, C435S320100
Reexamination Certificate
active
10035216
ABSTRACT:
The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed.
REFERENCES:
patent: 5275942 (1994-01-01), Vos
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5691177 (1997-11-01), Guber et al.
patent: 5695967 (1997-12-01), Van Bokkelen et al.
patent: 5741486 (1998-04-01), Pathak et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5763217 (1998-06-01), Cynader et al.
patent: 5763242 (1998-06-01), Zhang et al.
patent: 5851808 (1998-12-01), Elledge et al.
patent: 5869294 (1999-02-01), Harrington et al.
patent: 5888732 (1999-03-01), Hartley et al.
patent: 5998208 (1999-12-01), Fraefel et al.
patent: 6143557 (2000-11-01), Hartley et al.
patent: 6143566 (2000-11-01), Heintz et al.
patent: 6171861 (2001-01-01), Hartley et al.
patent: 6270969 (2001-08-01), Hartley et al.
patent: 6277608 (2001-08-01), Hartley et al.
patent: 6277621 (2001-08-01), Horsburgh et al.
patent: WO 93/12233 (1993-06-01), None
patent: WO 95/06486 (1995-03-01), None
patent: WO 97/05263 (1997-02-01), None
patent: WO 99/06582 (1999-02-01), None
patent: WO 00/12693 (2000-03-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 00/29000 (2000-05-01), None
patent: WO 00/34497 (2000-06-01), None
patent: WO 00/52027 (2000-09-01), None
patent: WO 01/31039 (2001-05-01), None
patent: WO 01/42509 (2001-06-01), None
Johnston et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther. Feb. 10, 1997;8(3):359-70.
Ebersole et al. (“Mammalian Artificial Chromosomes: Prospects for Gene Therapy” in Gene Therapy Technologies, Applications and Regulations (Meager, A., Ed.) © 1999, John Wiley & Sons Ltd, pp. 165-178.
Kim et al. Modification of bacterial artificial chromosome clones using Cre recombinase: introduction of selectable markers for expression in eukaryotic cells, Genome Res. Apr. 1998;8(4):404-12.
Saeki et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. Dec. 10, 1998;9(18):2787-94.
Wang et al. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol. Dec. 1996;70(12):8422-30.
Woodfield et al. Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3′-para-nitrophenyl phosphate ester. Nucleic Acids Res. Sep. 1, 2000;28(17):3323-31.
Aboody-Guterman, K.S., et al., “Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo,” Neuroreport 8:3801-3808, Rapid Science Publishers (1997).
Altshuler, D., et al., “Guilt by association,”Nat. Genet. 26:135-137, Nature Publishing Co. (Oct. 2000).
Antoch, M.P., et al., “Functional Identification of the Mouse Circadian Clock Gene by Transgenic BAC Rescue,”Cell 89:655-667, Cell Press (1997).
Banerjee, S., et al., “Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus,”Nat. Med. 1:1303-1308, Nature Publishing Co. (1995).
Bilbao, G., et al., “Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo,”FASEB J. 11:624-634, Federation of American Societies for Experimental Biology (1997).
Blackwood, E.M. and Kadonaga, J.T., “Going the Distance: A Current View of Enhancer Action,”Science 281:60-63, American Association for the Advancement of Science (1998).
Bobo, R.H., et al., “Convection-enhanced delivery of macromolecules in the brain,”Proc. Natl. Acad. Sci. 91:2076-2080, National Academy of Sciences (1994).
Breakfield, X.O., et al., “4. Herpes Simplex Virus Vectors for Tumor Therapy,” in:The Internet Book of Gene Therapy: Cancer Therapeutics, Sobol, R.E. and Scanlon, K.J., eds., Appleton and Lange, Stamford, Connecticut, pp. 41-56 (1995).
Brune, W., et al., “Forward with BACs new tools for herpesvirus genomics,”Trends Genet. 16:254-259, Elsevier Trends Journals (Jun. 2000).
Caskey, C.T. and Kruh, G.D., “The HPRT Locus,”Cell16:1-9, Massachusetts Institute of Technology (1979).
Chase, M., et al., “An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,”Nat. Biotechnol. 16:444-448, Nature Publishing Co. (1998).
Compton, S.H., et al., “Stable integration of large (>100kb) PAC constructs in HaCaT keratinocytes using an integrin-targeting peptide delivery system,”Gene Ther. 7:1600-1605, Macmillan Publishers Ltd. (Sep. 2000).
Cunningham, C. and Davidson, A.J., “A Cosmid-Based System for Constructing Mutants of Herpes Simplex Virus Type 1,”Virology 197:116-124, Academic Press, Inc. (1993).
Davidson, B.L., et al., “Identification of 17 Independent Mutations Responsible for Human Hypoxanthine-Guanine Phosphoribosyltransferase (HPRT) Deficiency,”Am. J. Hum. Genet. 48:951-958, University of Chicago Press (1991).
Davidson, B.L., et al., “A model system for in vivo gene transfer into the central nervous system using an adenoviral vector,”Nat. Genet. 3:219-223, Nature Publishing Co. (1993).
Delecluse, H.-J., et al., “Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells,”Proc. Natl. Acad. Sci. USA 95:8245-8250, National Academy of Sciences (1998).
Dornburg, R., “Reticuloendotheliosis viruses and derived vectors,”Gene. Ther. 2:301-310, Stockton Press (1995).
During, M.J., et al., “Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase,”Science 266:1399-1403, American Association for the Advancement of Science (1994).
Evans, G.A., et al., “High efficiency vectors for cosmid microcloning and genomic analysis,”Gene 79:9-20, Elsevier Science B.V. (1989).
Feng, M., et al., “Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector,”Nat. Biotechnol. 15:866-870, Nature Publishing Co. (1997).
Flotte, T.R. and Carter, B.J., “Adeno-associated virus vectors for gene therapy,”Gene Ther. 2:357-362, Stockton Press (1995).
Fraefel, C., et al., “Helper Virus-Free Transfer of Herpes Simplex Virus Type 1 Plasmid Vectors into Neural Cells,”J. Virol. 70:7190-7197, American Society for Microbiology (1996).
Fraefel, C., et al., “Gene Transfer into Hepatocytes Mediated by Helper Virus-Free HSV/AAV Hybrid Vectors,”Mol. Med. 3:813-825, Springer (1997).
Fraefel, C., et al., “4. HSV-1 Amplicon,” in:Gene Therapy for Neurological Disorders and Brain Tumors,Chiocca, E.A. and Breakefield, X.O., eds., Humana Press, Totowa, New Jersey, pp. 63-82 (1998).
Gardella, T., et al., “Detection of Circular and Linear Herpesvirus DNA Molecules in Mammalian Cells by Gel Electrophoresis,”J. Virol. 50:248-254, A
Chiocca E. Antonio
Saeki Yoshinaga
Wade-Martins Richard
Sterne Kessler Goldstein & Fox P.L.L.C.
Sullivan Daniel M.
The General Hospital Corporation
LandOfFree
Viral delivery system for infectious transfer of large... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral delivery system for infectious transfer of large..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral delivery system for infectious transfer of large... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789976